How to Use Natriuretic Peptides in Patients with Heart Failure with Non-Reduced Ejection Fraction? A Position Paper from the Heart Failure Working Group of Turkish Society of Cardiology

dc.authoridÇELİK, AHMET/0000-0002-9417-7610
dc.authoridGüvenç, Tolga Sinan/0000-0002-6738-266X
dc.authoridYILMAZ, Mehmet Birhan/0000-0002-8169-8628
dc.authorwosidCavusoglu, Yuksel/JWA-0879-2024
dc.authorwosidÇELİK, AHMET/AAA-6615-2021
dc.authorwosidGüvenç, Tolga Sinan/AAK-6020-2020
dc.authorwosidYILMAZ, Mehmet Birhan/Y-1372-2019
dc.contributor.authorCelik, Ahmet
dc.contributor.authorKilicaslan, Baris
dc.contributor.authorTemizhan, Ahmet
dc.contributor.authorGuvenc, Tolga Sinan
dc.contributor.authorAltay, Hakan
dc.contributor.authorCavusoglu, Yuksel
dc.contributor.authorYilmaz, Mehmet Birhan
dc.date.accessioned2024-05-19T14:39:40Z
dc.date.available2024-05-19T14:39:40Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractNatriuretic peptides are widely used in all types of heart failure. Previously, we defined heart failure with non-reduced ejection fraction as patients with heart failure symptoms and/or signs and who have left ventricular ejection fraction > 40%.(1) For the diagnosis of heart failure with preserved ejection fraction, the presence of raised natriuretic peptides is one of the major components of the diagnosis, and raised natriuretic peptides make the diagnosis more likely in patients with heart failure with mildly reduced ejection fraction.(2) The majority of the existing studies have described the utility of natriuretic peptides in patients with heart failure with reduced ejection fraction, but there is not enough data on natriuretic peptides in heart failure patients with heart failure with non-reduced ejection fraction. Despite the insufficient information regarding the usage of natriuretic peptides in heart failure with non-reduced ejection fraction, it is obvious that there is an unmet need to guide how to use natriuretic peptides in these patients. The main goal of this article is to discuss the role of natriuretic peptides in diagnosis, prognosis, and guidance of heart failure treatment in patients with heart failure with non-reduced ejection fraction. The present review discusses the role of natriuretic peptides in heart failure with non-reduced ejection fraction focusing on: the characteristics of natriuretic peptides, primary prevention of heart failure, diagnosis of heart failure with non-reduced ejection fraction in different patient characteristics and comorbidities, prognosis of heart failure, monitoring of heart failure treatment and, how to use in worsening heart failure.en_US
dc.identifier.doi10.14744/AnatolJCardiol.2023.3297
dc.identifier.endpage318en_US
dc.identifier.issn2149-2263
dc.identifier.issn2149-2271
dc.identifier.issue6en_US
dc.identifier.pmid37257015en_US
dc.identifier.scopus2-s2.0-85160690426en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage308en_US
dc.identifier.trdizinid1179787en_US
dc.identifier.urihttps://doi.org10.14744/AnatolJCardiol.2023.3297
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1179787
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4826
dc.identifier.volume27en_US
dc.identifier.wosWOS:001070506600005en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherKare Publen_US
dc.relation.ispartofAnatolian Journal of Cardiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectB-Type Natriuretic Peptideen_US
dc.subjectHeart Failureen_US
dc.subjectHeart Failureen_US
dc.subjectChronicen_US
dc.titleHow to Use Natriuretic Peptides in Patients with Heart Failure with Non-Reduced Ejection Fraction? A Position Paper from the Heart Failure Working Group of Turkish Society of Cardiologyen_US
dc.typeArticleen_US

Dosyalar